Publications by authors named "B Susi"
In recent decades, an incredible evolution in antithrombotic therapies used for treating patients with atherosclerosis, atrial fibrillation, and venous thromboembolism has been observed, leading to the availability of increasingly safe drugs. Nonetheless, bleeding complications remain a significant concern, with considerable health, social, and economic implications. To improve the acute management of patients experiencing or at risk for major bleeding events, specific reversal agents for antithrombotic drugs have been recently developed.
View Article and Find Full Text PDFArticle Synopsis
- * New reversal agents for these antithrombotic drugs have been developed to manage major bleeding events effectively, showing promise in initial studies.
- * The consensus document by ANMCO/SIMEU details these reversal agents' characteristics and suggests practical guidelines for their use in patients experiencing or at risk of severe bleeding.
We evaluated the application and clinical impact of multi-gene pharmacogenetic testing in oncology palliative medicine. In a single-arm pilot trial, cancer patients with uncontrolled pain were assessed in a palliative medicine clinic at baseline and received pharmacogenetic testing. Results were used as applicable up to the final visit (day 30).
View Article and Find Full Text PDFPurpose: Approximately 30% of patients with cancer who have pain have symptomatic improvement within 1 month using conventional pain management strategies. Engaging clinical pharmacists in palliative medicine (PM) and use of pharmacogenomic testing may improve cancer pain management.
Methods: Adult patients with cancer with uncontrolled pain had baseline assessments performed by PM providers using the Edmonton Symptom Assessment Scale.